Global Contact Us About Our commitment Research Our MedicineInvestors & Media Careers GERMANY Our mission: to enable underserved patients to receive therapy Global Blood Therapeutics (GBT) is dedicated to the research, development and delivery of therapies for people living with serious blood diseases - starting with sickle cell disease. Our goal is to fundamentally change the treatment of the often overlooked and rare sickle cell disease. Several million people worldwide are affected by the disease. In Europe alone there are an estimated 1 52,000 . The hereditary disease particularly affects people of sub-Saharan, Hispanic, South Asian or southern European descent as well as people from the Middle East. GBT is driven by the urgency to address problems in the affected communities. These include existing racist prejudices, poor access to the health system, lower life expectancy and a lack of therapeutic innovations. GBT is advancing the development of novel therapies for the treatment of sickle cell disease to improve the care of those living with this serious, previously incurable disease. Together with doctors and representatives of affected patients, GBT concentrates on raising awareness of sickle cell disease and giving patients better access to care. Facts about sickle cell disease in Germany The immigration of people from countries where the disease predominantly occurs is increasing steadily. There are approximately 3,000 children and adults living with sickle cell disease. 2 Sickle cell disease occurs in around 1 in 12,000 people in Germany. 3 Seit März 2021 ist die Sichelzellkrankheit Teil des Neugeborenenscreenings.4 Die Verbreitung der Sichelzellkrankheit nimmt auch außerhalb von Deutschland in Europa von Jahr zu Jahr zu. Hier finden Sie eine detaillierte Übersicht zum Umfeld der Sichelzellkrankheit in Deutschland und anderen ausgewählten europäischen Ländern. Wir alle bei GBT leben jeden Tag unsere gemeinsamen kulturellen Werte: INNOVATION Mit Wissenschaft und Kreativität den Status quo in Frage stellen INKLUSION Ein Team schaffen, in dem jeder gehört wird VERANTWORTUNG Versprechen halten und das Richtige tun GEMEINSCHAFT Konzentriert auf unsere Mission und mit Hingabe für unsere Patient:innen, Mitarbeiter:innen und Partner:innen Kontakt : GBT Germany GmbH Potsdamer Platz 1 7. Stock 10785 Berlin Deutschland info.germany@gbt.com +49 (30) 800 98154 Ansicht auf Google Maps 1EMA: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3182125 Last accessed July 2021 2https://www.onkopedia.com/de/onkopedia/guidelines/sichelzellkrankheiten/@@guideline/html/index.html 3Kunz JB, Awad S, Happich M, Muckenthaler L, Lindner M, Gramer G, Okun JG, Hoffmann GF, Bruckner T, Muckenthaler MU, Kulozik AE. Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. Ann Hematol. 2016 Feb;95(3):397-402. doi: 10.1007/s00277-015-2573-y. Epub 2015 Dec 12. PMID: 26658910. 4 https://www.kbv.de/media/sp/2020_11_20_Kinder_Sichelzellen_BAnz.pdf gbt Copyright 2021 Global Blood Therapeutics, Inc. Privacy Policy Online Tracking Opt-Out Guide Terms Of Use Community Guidelines P-VOX-US-00501 ABOUT Our Company Leadership Board of Directors Contact Us CAREERS OUR COMMITMENT Patients & Advocacy GBT's Supported Conferences COVID-19 Information and Resources Corporate giving The GBT Foundation Expanded Access RESEARCH Sickle Cell Disease pipeline Externally Sponsored Research (ESR) Partnerships Publications OUR MEDICINE INVESTORS & MEDIA Company summary Media Resources Press releases Events & Presentations Quarterly Results Analyst coverage Stock information SEC filings Governance Investor FAQs This site uses cookies to give you the best online experience. Learn more, including how to disable certain cookies on our Privacy Page .Accept × The health and safety of patients, healthcare professionals and our employees is our highest priority. Learn more about our response to the COVID-19 pandemic, including the direct support we are providing to the sickle cell disease community. COVID-19 Information and Resources Close